Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Agilent Names Massachusetts Eye and Ear Infirmary as Certified Service Provider for NGS and aCGH Solutions

Published: Thursday, October 24, 2013
Last Updated: Thursday, October 24, 2013
Bookmark and Share
MEEI's Department of Ophthalmology Ocular Genomics Institute is working to harness the power of genomics and gene therapy to advance the knowledge and treatment of blinding eye diseases.

Agilent Technologies announced that the Massachusetts Eye and Ear Infirmary, an affiliate of Harvard Medical School, has been authorized as a Certified Service Provider of Agilent's next-generation target enrichment and microarray-based comparative genomic hybridization (aCGH) solutions. 

"Becoming an Agilent CSP enables us to provide the ocular genomics research community with access to the latest protocols and technologies we are using at Mass. Eye and Ear with ever-increasing success," said Dr. Eric Pierce, director of the Ocular Genomics Institute. "It is our hope that these tools will help advance studies in genomic research and gene therapy. In addition, incorporating the Agilent Bravo Automated Liquid Handling platform into our service offerings will enable us to quickly process large volumes of samples for even more researchers and for a wide range of genomics applications. We are using these approaches to provide improved clinical genetic diagnostic testing services for patients with inherited eye disorders."

"We are excited to have MEEI as part of the Agilent CSP program," said Victor Fung, senior director of marketing for Agilent's Genomics Solutions Division. "MEEI has used Agilent's NGS target enrichment and aCGH solutions for several years in their retinal degeneration mutational disease research. We look forward to supporting them as they expand their services outside of the Harvard community."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent’s Non-Small Cell Lung Cancer Companion Dx Receives Expanded FDA Approval
Agilent’s Dako PD-L1 IHC 22C3 pharmDx has an expanded label approved by the U.S. FDA for use in determining PD-L1 expression status to inform treatment in metastatic non-small cell lung cancer with KEYTRUDA® (pembrolizumab).
Tuesday, October 25, 2016
Agilent, Burning Rock Sign Agreement on Molecular Diagnostics
Companies collaborate in their aim to accelerate accurate diagnosis of cancer for patients in China.
Thursday, September 29, 2016
Impact of Emerging Contaminants in Our Water Supply
Emerging contaminants, any synthetic or naturally occurring chemical not commonly monitored in the environment, in our water supply are becoming of increasing concern due to their potential ecological and/or human health effects.
Friday, September 16, 2016
Agilent Technologies to Build New Facility in Colorado
Agilent buys 20 acres in Weld County to increase pharmaceutical manufacturing capacity.
Wednesday, August 10, 2016
Dako Announces CE Mark for Companion Diagnostic
Dako has announced the CE Mark certification for use of PD-L1, a companion diagnostic to Merck's anti-PD-1 immunotherapy Keytruda.
Thursday, August 04, 2016
Agilent to Acquire iLab Solutions
Companies have announced they have signed a definitive agreement under which Agilent will acquire substantially all of the assets of iLab, the market leader in cloud-based solutions for core laboratory management.
Wednesday, June 29, 2016
Agilent, Eurofins Genomics Collaborate
Agilent plans to offer custom components and an assembled plasmid service for Agilent’s SureVector next-generation cloning kits through a collaboration with Eurofins.
Monday, March 14, 2016
Best Practices for Breast Cancer Diagnosis
Agilent has published “Breast Cancer Diagnosis: Past, Present and Future,” a white paper on the use of immunohistochemistry in diagnosing and treating breast cancer.
Monday, March 14, 2016
Agilent Invests $80M in Lasergen
Company has announced that it has invested $80 million in Lasergen, with innovative next-generation sequencing technology for clinical applications.
Friday, March 11, 2016
Agilent Technologies Announces Early Access to Custom guideRNA for Functional Genomics
Company has announced a program that gives biologists conducting functional genomics research early access to a potential new resource.
Saturday, February 13, 2016
Agilent Technologies and 10x Genomics Announce Collaboration
Company has announced collaboration to develop a premium exome that provides a streamlined workflow for 10x Genomics'Chromium platform.
Friday, February 12, 2016
Agilent Wins Award for Innovation in LC
Dual-needle technology enhances speed, flexibility.
Thursday, January 28, 2016
Agilent Extends Agreement with PerkinElmer on Bioanalyzer Chips
PerkinElmer supplies chips for Agilent's popular 2100 Bioanalyzer system.
Thursday, January 21, 2016
Agilent Signs Agreement with Thermo Fisher Scientific
Agreement to exchange instrument controls to improve the productivity and user experience.
Thursday, November 12, 2015
Agilent Completes Acquisition of Seahorse Bioscience
Agilent has completed the acquisition of Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics.
Tuesday, November 03, 2015
Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Editing Gene Mutations in Anemia
Researchers successfully use a new gene editing strategy to correct mutations that cause a form of anemia.
Genes Help Track Odd Migrations of Zika Mosquitoes
Study shows that mosquitoes carrying Zika virus or Dengue fever a genetically distinct around the world.
Nanomedicine Aims to Improve HIV Drug Therapies
New research aims to improve the administration and availability of drug therapies to HIV patients using nanotechnology.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
Gene Editing Corrects Sickle Cell Mutation
Researchers demonstrate a potential pathway to developing gene-editing treatments for sickle cell disease.
Driving Mosquito Evolution to Fight Malaria
Researchers propose insect repellent in conjunction with insecticides to extend current insecticide lifetime.
Lab-on-a-Chip to Help Detect Cancer
In this podcast, we speak to Gustavo Stolovitsky to learn about his career and the work he is doing at IBM Research.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos